Download PDF
Semin Liver Dis 2005; 25(4): 461-472
DOI: 10.1055/s-2005-923317
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Iron in Nonhemochromatotic Liver Disorders

Vamsee Alla1 , Herbert L. Bonkovsky1 , 2
  • 1Departments of Medicine and Molecular, Microbial, and Structural Biology and The Liver-Biliary-Pancreatic Center, The University of Connecticut Health Center, Farmington, Connecticut
  • 2Professor
Further Information

Publication History

Publication Date:
29 November 2005 (online)

    Permissions and Reprints

ABSTRACT

Iron is essential for cellular functions, but in excessive amounts it is toxic to cells. The harmful effects are related to increased oxidative stress and production of reactive oxygen species causing oxidative damage to lipids, proteins, and nucleic acids. Heavy iron overload as occurs in primary and secondary hemochromatosis can cause fibrosis of various parenchymal organs such as the liver, heart, and pancreas. Lesser degrees of hepatic iron deposition are also associated with, and seem to be risk factors for, certain nonhemochromatotic liver diseases. Porphyria cutanea tarda is associated with hepatic iron overload and responds to iron-reduction therapy. Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages. In this article we review selected nonhemochromatotic disorders in which iron can play an important comorbid role.

KEYWORDS

Alcohol - cirrhosis - hepatitis C - iron - nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - porphyria cutanea tarda

REFERENCES

  • 1 Ioannou G N, Dominitz J A, Weiss N S, Heagerty P J, Kowdley K V. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia.  Gastroenterology. 2004;  126 1293-1301
    CrossrefPubMedGoogle Scholar
  • 2 Bonkovsky H L, Obando J V. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.  Curr Gastroenterol Rep. 1999;  1 30-37
    PubMedGoogle Scholar
  • 3 Milman N, Graudal N, Hegnhoj J, Christoffersen P, Pedersen N S. Relationships among serum iron status markers, chemical and histochemical liver iron content in 117 patients with alcoholic and non-alcoholic hepatic disease.  Hepatogastroenterology. 1994;  41 20-24
    PubMedGoogle Scholar
  • 4 De Feo T M, Fargion S, Duca L et al.. Non-transferrin-bound iron in alcohol abusers.  Alcohol Clin Exp Res. 2001;  25 1494-1499
    PubMedGoogle Scholar
  • 5 Suzuki Y, Saito H, Suzuki M et al.. Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease.  Alcohol Clin Exp Res. 2002;  26(8 Suppl) 26S-31S
    PubMedGoogle Scholar
  • 6 Pascoe A, Kerlin P, Steadman C et al.. Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation.  Gut. 1999;  45 301-305
    PubMedGoogle Scholar
  • 7 Pascoe A, Kerlin P, Jones D. Spur cell anemia explains the iron overload in advanced cirrhosis (C282Y negative).  Hepatology. 2000;  32 159
    CrossrefPubMedGoogle Scholar
  • 8 Mazzanti R, Srai K S, Debnam E S, Boss A M, Gentilini P. The effect of chronic ethanol consumption on iron absorption in rats.  Alcohol Alcohol. 1987;  22 47-52
    PubMedGoogle Scholar
  • 9 Duane P, Raja K B, Simpson R J, Peters T J. Intestinal iron absorption in chronic alcoholics.  Alcohol Alcohol. 1992;  27 539-544
    PubMedGoogle Scholar
  • 10 Bonkovsky H L, Lambrecht R W, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease.  Alcohol. 2003;  30 137-144
    CrossrefPubMedGoogle Scholar
  • 11 Harrison-Findik D, Schafer D, Klein E, Gollan J. Hepatic hepcidin expression is regulated by ethanol and acetaldehyde: role of IL-6 and oxidative stress. BioIron 2005: Prague, Czech Republic 2005: 24
    Google Scholar
  • 12 Nemeth E, Tuttle M S, Powelson J et al.. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.  Science. 2004;  306 2090-2093
    CrossrefPubMedGoogle Scholar
  • 13 Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease.  N Engl J Med. 2004;  350 2383-2397
    CrossrefPubMedGoogle Scholar
  • 14 Sabesin S M, Thomas L B. Parenchymal siderosis in patients with preexisting portal cirrhosis. A pathologic entity simulating idiopathic and transfusional hemochromatosis.  Gastroenterology. 1964;  46 477-485
    PubMedGoogle Scholar
  • 15 Powell L W. Normal human iron storage and its relation to ethanol consumption.  Australas Ann Med. 1966;  15 110-115
    PubMedGoogle Scholar
  • 16 Lundvall O, Weinfeld A, Lundin P. Iron stores in alcohol abusers. I. Liver iron.  Acta Med Scand. 1969;  185 259-269
    PubMedGoogle Scholar
  • 17 Jakobovits A W, Morgan M Y, Sherlock S. Hepatic siderosis in alcoholics.  Dig Dis Sci. 1979;  24 305-310
    CrossrefPubMedGoogle Scholar
  • 18 MacDonald R A. Primary hemochromatosis: inherited or acquired?.  Prog Hematol. 1966;  5 324-353
    PubMedGoogle Scholar
  • 19 Regoeczi E, Chindemi P A, Debanne M T. Transferrin glycans: a possible link between alcoholism and hepatic siderosis.  Alcohol Clin Exp Res. 1984;  8 287-292
    PubMedGoogle Scholar
  • 20 Beguin Y, Bergamaschi G, Huebers H A, Finch C A. The behavior of asialotransferrin-iron in the rat.  Am J Hematol. 1988;  29 204-210
    PubMedGoogle Scholar
  • 21 Rouach H, Houze P, Gentil M, Orfanelli M T, Nordmann R. Effects of acute ethanol administration on the uptake of 59Fe-labeled transferrin by rat liver and cerebellum.  Biochem Pharmacol. 1994;  47 1835-1841
    CrossrefPubMedGoogle Scholar
  • 22 Chapman R W, Morgan M Y, Boss A M, Sherlock S. Acute and chronic effects of alcohol on iron absorption.  Dig Dis Sci. 1983;  28 321-327
    CrossrefPubMedGoogle Scholar
  • 23 Tsukamoto H, Horne W, Kamimura S et al.. Experimental liver cirrhosis induced by alcohol and iron.  J Clin Invest. 1995;  96 620-630
    CrossrefPubMedGoogle Scholar
  • 24 Adams P C, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings.  Hepatology. 1996;  23 724-727
    CrossrefPubMedGoogle Scholar
  • 25 Loreal O, Deugnier Y, Moirand R et al.. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients.  J Hepatol. 1992;  16(1-2) 122-127
    CrossrefPubMedGoogle Scholar
  • 26 Fargion S, Mandelli C, Piperno A et al.. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis.  Hepatology. 1992;  15 655-659
    PubMedGoogle Scholar
  • 27 Fargion S, Fracanzani A L, Piperno A et al.. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis.  Hepatology. 1994;  20 1426-1431
    CrossrefPubMedGoogle Scholar
  • 28 Fletcher L M, Powell L W. Hemochromatosis and alcoholic liver disease.  Alcohol. 2003;  30 131-136
    CrossrefPubMedGoogle Scholar
  • 29 Grove J, Daly A K, Burt A D et al.. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease.  Gut. 1998;  43 262-266
    CrossrefPubMedGoogle Scholar
  • 30 Thursz M, Mantafounis D, Yallo R. Severe alcoholic liver disease is associated with the haemochromatosis gene mutant.  Gastroenterology. 1997;  112 A1401
    PubMedGoogle Scholar
  • 31 Frenzer A, Rudzki Z, Norton I D, Butler W J, Roberts-Thomson I C. Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis.  Scand J Gastroenterol. 1998;  33 1324
    CrossrefPubMedGoogle Scholar
  • 32 Raynard B, Balian A, Fallik D et al.. Risk factors of fibrosis in alcohol-induced liver disease.  Hepatology. 2002;  35 635-638
    CrossrefPubMedGoogle Scholar
  • 33 Bonkovsky H L, Banner B F, Lambrecht R W, Rubin R B. Iron in liver diseases other than hemochromatosis.  Semin Liver Dis. 1996;  16 65-82
    PubMedGoogle Scholar
  • 34 Bonkovsky H L, Poh-Fitzpatrick M, Pimstone N et al.. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America.  Hepatology. 1998;  27 1661-1669
    CrossrefPubMedGoogle Scholar
  • 35 Bonkovsky H L, Lambrecht R W. Iron-induced liver injury.  Clin Liver Dis. 2000;  4 409-429 vi-viii
    CrossrefPubMedGoogle Scholar
  • 36 Lambrecht R W, Bonkovsky H L. Hemochromatosis and porphyria.  Semin Gastrointest Dis. 2002;  13 109-119
    PubMedGoogle Scholar
  • 37 Elder G H, Sheppard D M, De Salamanca R E, Olmos A. Identification of two types of porphyria cutanea tarda by measurement of erythrocyte uroporphyrinogen decarboxylase.  Clin Sci (Lond). 1980;  58 477-484
    PubMedGoogle Scholar
  • 38 Koszo F, Morvay M, Dobozy A, Simon N. Erythrocyte uroporphyrinogen decarboxylase activity in 80 unrelated patients with porphyria cutanea tarda.  Br J Dermatol. 1992;  126 446-449
    PubMedGoogle Scholar
  • 39 Elder G H, Urquhart A J, De Salamanca R E, Munoz J J, Bonkovsky H L. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda.  Lancet. 1985;  2 229-233
    PubMedGoogle Scholar
  • 40 Gorman N, Ross K L, Walton H S et al.. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron.  Hepatology. 2002;  35 912-921
    CrossrefPubMedGoogle Scholar
  • 41 Sinclair P R, Gorman N, Walton H S et al.. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron.  Toxicol Appl Pharmacol. 2000;  162 60-67
    CrossrefPubMedGoogle Scholar
  • 42 Sinclair P R, Gorman N, Dalton T et al.. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice.  Biochem J. 1998;  330(Pt 1) 149-153
    PubMedGoogle Scholar
  • 43 Smith A G, Clothier B, Carthew P et al.. Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.  Toxicol Appl Pharmacol. 2001;  173 89-98
    CrossrefPubMedGoogle Scholar
  • 44 Sinclair P R, Gorman N, Trask H W et al.. Uroporphyria caused by ethanol in Hfe(-/-) mice as a model for porphyria cutanea tarda.  Hepatology. 2003;  37 351-358
    CrossrefPubMedGoogle Scholar
  • 45 Roberts A G, Whatley S D, Morgan R R, Worwood M, Elder G H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda.  Lancet. 1997;  349 321-323
    CrossrefPubMedGoogle Scholar
  • 46 Bulaj Z J, Phillips J D, Ajioka R S et al.. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.  Blood. 2000;  95 1565-1571
    PubMedGoogle Scholar
  • 47 Egger N G, Goeger D E, Payne D A, Miskovsky E P, Weinman S A, Anderson K E. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.  Dig Dis Sci. 2002;  47 419-426
    PubMedGoogle Scholar
  • 48 Tannapfel A, Stolzel U, Kostler E et al.. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients.  Virchows Arch. 2001;  439 1-5
    PubMedGoogle Scholar
  • 49 Stuart K A, Busfield F, Jazwinska E C et al.. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients.  J Hepatol. 1998;  28 404-409
    CrossrefPubMedGoogle Scholar
  • 50 Sampietro M, Piperno A, Lupica L et al.. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda.  Hepatology. 1998;  27 181-184
    CrossrefPubMedGoogle Scholar
  • 51 Clark J M, Brancati F L, Diehl A M. The prevalence and etiology of elevated aminotransferase levels in the United States.  Am J Gastroenterol. 2003;  98 960-967
    CrossrefPubMedGoogle Scholar
  • 52 Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease.  Gastroenterology. 2002;  122 1649-1657
    CrossrefPubMedGoogle Scholar
  • 53 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc. 1980;  55 434-438
    PubMedGoogle Scholar
  • 54 Day C P, James O F. Steatohepatitis: a tale of two “hits”?.  Gastroenterology. 1998;  114 842-845
    CrossrefPubMedGoogle Scholar
  • 55 Loguercio C, De S T, D'Auria M V et al.. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver.  Dig Liver Dis. 2004;  36 398-405
    CrossrefPubMedGoogle Scholar
  • 56 Marchesini G, Brizi M, Morselli-Labate A M et al.. Association of nonalcoholic fatty liver disease with insulin resistance.  Am J Med. 1999;  107 450-455
    Google Scholar
  • 57 Marchesini G, Brizi M, Bianchi G et al.. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.  Diabetes. 2001;  50 1844-1850
    CrossrefPubMedGoogle Scholar
  • 58 Knobler H, Schattner A, Zhornicki T et al.. Fatty liver-an additional and treatable feature of the insulin resistance syndrome.  QJM. 1999;  92 73-79
    CrossrefPubMedGoogle Scholar
  • 59 Cortez-Pinto H, Camilo M E, Baptista A, De Oliveira A G, De Moura M C. Non-alcoholic fatty liver: another feature of the metabolic syndrome?.  Clin Nutr. 1999;  18 353-358
    PubMedGoogle Scholar
  • 60 Tankurt E, Biberoglu S, Ellidokuz E et al.. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis.  J Hepatol. 1999;  31 963
    PubMedGoogle Scholar
  • 61 Sanyal A J, Campbell-Sargent C, Mirshahi F et al.. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.  Gastroenterology. 2001;  120 1183-1192
    CrossrefPubMedGoogle Scholar
  • 62 Willner I R, Waters B, Patil S R, Reuben A, Morelli J, Riely C A. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.  Am J Gastroenterol. 2001;  96 2957-2961
    CrossrefPubMedGoogle Scholar
  • 63 Loguercio C, De Girolamo V, de Sio I et al.. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.  J Hepatol. 2001;  35 568-574
    PubMedGoogle Scholar
  • 64 Chitturi S, Abeygunasekera S, Farrell G C et al.. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome.  Hepatology. 2002;  35 373-379
    CrossrefPubMedGoogle Scholar
  • 65 Pagano G, Pacini G, Musso G et al.. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.  Hepatology. 2002;  35 367-372
    CrossrefPubMedGoogle Scholar
  • 66 Comert B, Mas M R, Erdem H et al.. Insulin resistance in non-alcoholic steatohepatitis.  Dig Liver Dis. 2001;  33 353-358
    PubMedGoogle Scholar
  • 67 Bacon B R, Farahvash M J, Janney C G, Neuschwander-Tetri B A. Nonalcoholic steatohepatitis: an expanded clinical entity.  Gastroenterology. 1994;  107 1103-1109
    PubMedGoogle Scholar
  • 68 George D K, Goldwurm S, MacDonald G A et al.. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.  Gastroenterology. 1998;  114 311-318
    CrossrefPubMedGoogle Scholar
  • 69 Bonkovsky H L, Jawaid Q, Tortorelli K et al.. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis.  J Hepatol. 1999;  31 421-429
    CrossrefPubMedGoogle Scholar
  • 70 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
    CrossrefPubMedGoogle Scholar
  • 71 Younossi Z M, Gramlich T, Bacon B R et al.. Hepatic iron and nonalcoholic fatty liver disease.  Hepatology. 1999;  30 847-850
    CrossrefPubMedGoogle Scholar
  • 72 Facchini F S, Hua N W, Stoohs R A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease.  Gastroenterology. 2002;  122 931-939
    CrossrefPubMedGoogle Scholar
  • 73 Desai T, Chiorean M. Phlebotomy reduces transaminase levels in patients with chronic non-alcoholic steatohepatitis.  Gastroenterology. 1998;  114 A1233
    PubMedGoogle Scholar
  • 74 Nitecki J, Jackson F, Allen M. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH).  Gastroenterology. 2000;  118 A1474
    PubMedGoogle Scholar
  • 75 Valenti L, Fracanzani A L, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance.  Gastroenterology. 2003;  124 866-867
    PubMedGoogle Scholar
  • 76 Fernandez-Real J M, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion.  Clin Chem. 2005;  51 1201-1205
    PubMedGoogle Scholar
  • 77 [No authors listed.] . Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.  J Viral Hepat. 1999;  6 35-47
    CrossrefPubMedGoogle Scholar
  • 78 Alter M J. Hepatitis C virus infection in the United States.  J Hepatol. 1999;  31(Suppl 1) 88-91
    CrossrefPubMedGoogle Scholar
  • 79 Tong M J, el-Farra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C.  N Engl J Med. 1995;  332 1463-1466
    CrossrefPubMedGoogle Scholar
  • 80 Seeff L B. The natural history of chronic hepatitis C virus infection.  Clin Liver Dis. 1997;  1 587-602
    PubMedGoogle Scholar
  • 81 Blumberg B S, Lustbader E D, Whitford P L. Changes in serum iron levels due to infection with hepatitis B virus.  Proc Natl Acad Sci USA. 1981;  78 3222-3224
    PubMedGoogle Scholar
  • 82 Di Bisceglie A M, Axiotis C A, Hoofnagle J H, Bacon B R. Measurements of iron status in patients with chronic hepatitis.  Gastroenterology. 1992;  102 2108-2113
    PubMedGoogle Scholar
  • 83 Arber N, Konikoff F M, Moshkowitz M et al.. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases.  Dig Dis Sci. 1994;  39 2656-2659
    CrossrefPubMedGoogle Scholar
  • 84 Bonkovsky H L, Banner B F, Rothman A L. Iron and chronic viral hepatitis.  Hepatology. 1997;  25 759-768
    CrossrefPubMedGoogle Scholar
  • 85 Shan Y, Lambrecht R W, Bonkovsky H L. Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey.  Clin Infect Dis. 2005;  40 834-841
    CrossrefPubMedGoogle Scholar
  • 86 Sartori M, Andorno S, La T G et al.. Evaluation of iron status in patients with chronic hepatitis C.  Ital J Gastroenterol Hepatol. 1998;  30 396-401
    PubMedGoogle Scholar
  • 87 Barton A L, Banner B F, Cable E E, Bonkovsky H L. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy.  Am J Clin Pathol. 1995;  103 419-424
    PubMedGoogle Scholar
  • 88 Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C.  Am J Gastroenterol. 1996;  91 1367-1373
    PubMedGoogle Scholar
  • 89 Van Thiel D H, Friedlander L, Fagiuoli S, Wright H I, Irish W, Gavaler J S. Response to interferon alpha therapy is influenced by the iron content of the liver.  J Hepatol. 1994;  20 410-415
    CrossrefPubMedGoogle Scholar
  • 90 Olynyk J K, Reddy K R, Di Bisceglie A M et al.. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.  Gastroenterology. 1995;  108 1104-1109
    PubMedGoogle Scholar
  • 91 Piperno A, Sampietro M, D'Alba R et al.. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C.  Liver. 1996;  16 248-254
    PubMedGoogle Scholar
  • 92 Fargion S, Fracanzani A L, Sampietro M et al.. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C.  Eur J Gastroenterol Hepatol. 1997;  9 497-503
    PubMedGoogle Scholar
  • 93 Fong T L, Han S H, Tsai N C et al.. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.  J Hepatol. 1998;  28 369-374
    CrossrefPubMedGoogle Scholar
  • 94 Fontana R J, Israel J, LeClair P et al.. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.  Hepatology. 2000;  31 730-736
    CrossrefPubMedGoogle Scholar
  • 95 Fargion S, Fracanzani A L, Rossini A et al.. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.  Am J Gastroenterol. 2002;  97 1204-1210
    PubMedGoogle Scholar
  • 96 Di Bisceglie A M, Bonkovsky H L, Chopra S et al.. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.  Hepatology. 2000;  32 135-138
    CrossrefPubMedGoogle Scholar
  • 97 Tsai N C, Zuckerman E, Han S H, Goad K, Redeker A G, Fong T L. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.  Am J Gastroenterol. 1997;  92 1831-1834
    PubMedGoogle Scholar
  • 98 Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron.  Am J Gastroenterol. 1994;  89 986-988
    PubMedGoogle Scholar
  • 99 Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R. Chronic hepatitis C is mild in menstruating women.  J Gastroenterol Hepatol. 2000;  15 1411-1417
    CrossrefPubMedGoogle Scholar
  • 100 Yano M, Hayashi H, Wakusawa S et al.. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C.  Am J Gastroenterol. 2002;  97 133-137
    CrossrefPubMedGoogle Scholar
  • 101 Kimura F, Hayashi H, Yano M et al.. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C.  Hepatogastroenterology. 2005;  52 563-566
    PubMedGoogle Scholar
  • 102 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
    CrossrefPubMedGoogle Scholar
  • 103 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
    CrossrefPubMedGoogle Scholar
  • 104 Bonkovsky H L. Iron as a comorbid factor in chronic viral hepatitis.  Am J Gastroenterol. 2002;  97 1-4
    CrossrefPubMedGoogle Scholar
  • 105 Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment.  Gut. 1997;  41 115-120
    CrossrefPubMedGoogle Scholar
  • 106 Piperno A, Vergani A, Malosio I et al.. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations.  Hepatology. 1998;  28 1105-1109
    CrossrefPubMedGoogle Scholar
  • 107 Smith B C, Gorve J, Guzail M A et al.. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.  Hepatology. 1998;  27 1695-1699
    CrossrefPubMedGoogle Scholar
  • 108 Kazemi-Shirazi L, Datz C, Maier-Dobersberger T et al.. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C.  Gastroenterology. 1999;  116 127-134
    PubMedGoogle Scholar
  • 109 Martinelli A L, Franco R F, Villanova M G et al.. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?.  Acta Haematol. 2000;  102 152-156
    PubMedGoogle Scholar
  • 110 Tung B Y, Emond M J, Bronner M P, Raaka S D, Cotler S J, Kowdley K V. Hepatitis C iron status, and disease severity: relationship with HFE mutations.  Gastroenterology. 2003;  124 318-326
    CrossrefPubMedGoogle Scholar
  • 111 Bonkovsky H L, Troy N, McNeal K et al.. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C.  J Hepatol. 2002;  37 848-854
    CrossrefPubMedGoogle Scholar
  • 112 de Sousa M, Porto G. The immunological system in hemochromatosis.  J Hepatol. 1998;  28(Suppl 1) 1-7
    PubMedGoogle Scholar
  • 113 Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection.  Gastroenterology. 2003;  124 1509-1523
    CrossrefPubMedGoogle Scholar
  • 114 Lustbader E D, Hann H W, Blumberg B S. Serum ferritin as a predictor of host response to hepatitis B virus infection.  Science. 1983;  220 423-425
    PubMedGoogle Scholar
  • 115 Park C H, Valore E V, Waring A J, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver.  J Biol Chem. 2001;  276 7806-7810
    CrossrefPubMedGoogle Scholar
  • 116 Knutson M D, Oukka M, Koss L M, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin.  Proc Natl Acad Sci USA. 2005;  102 1324-1328
    CrossrefPubMedGoogle Scholar
  • 117 Roetto A, Papanikolaou G, Politou M et al.. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.  Nat Genet. 2003;  33 21-22
    CrossrefPubMedGoogle Scholar
  • 118 Detivaud L, Nemeth E, Boudjema K et al.. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function.  Blood. 2005;  106 746-748
    CrossrefPubMedGoogle Scholar
  • 119 Ohtake T, Inoue M, Miyoshi S, Suzuki Y, Saito H, Kohgo Y. Hepcidin is decreased in alcohol abuse. BioIron 2005: Prague, Czech Republic. 2005: 73
    Google Scholar
  • 120 Aoki C A, Rossaro L, Ramsamooj R, Brandhagen D, Burritt M F, Bowlus C L. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C.  J Clin Gastroenterol. 2005;  39 71-74
    PubMedGoogle Scholar

Herbert L BonkovskyM.D. 

MC-1111, University of Connecticut Health Center

263 Farmington Ave., Farmington, CT 06030

Email: bonkovsky@uchc.edu

      >